ArticleJournal of dental sciences2026
Gastric parietal cell and thyroid autoantibodies in patients with oral lichen planus.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Gastric parietal cell antibody (GPCA), thyroglobulin antibody (TGA), and thyroid microsomal antibody (TMA) are organ-specific autoantibodies associated with autoimmune disorders. This study primarily aimed to determine the frequencies of serum GPCA, TGA, and TMA positivity in patients with oral lichen planus (OLP). Materials and methods: Serum levels of GPCA, TGA, and TMA were evaluated in 588 OLP patients and in 588 age- and sex-matched healthy control subjects. Results: Among 588 OLP patients, 23.6 %, 27.4 %, and 28.4 % tested positive for GPCA, TGA, and TMA, respectively, compared with 2.2 %, 2.0 %, and 2.6 % in the control group. Each autoantibody was significantly more prevalent in OLP patients than in healthy control subjects (all Conclusion: Approximately 48.1 % of the 588 OLP patients demonstrated positivity for GPCA, TGA, and/or TMA. GPCA-positive individuals may be at risk for pernicious anemia, autoimmune atrophic gastritis, and gastric carcinoma, and TGA/TMA-positive individuals may exhibit thyroid dysfunction; thus, these autoantibody-positive patients should be referred for appropriate medical evaluation and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.